Download FREE PDF Brochure@ http://tinyurl.com/jcosl3g The neuromodulation market is segmented on the basis of technology, application, and region. The global neuromodulation market is expected to grow at a CAGR of 11.2% from 2015 to 2020, to reach $6.20 Billion by 2020 from $3.65 Billion in 2015. Factors such as rising geriatric population, increasing prevalence of neurological diseases, strong product pipeline offered by the players, and expanded target applications and new indications are driving the growth of this market. Moreover, expansion in emerging economies is likely to create significant growth opportunities for players operating in the neuromodulation market. However, factors such as unfavorable reimbursement scenario and lack of trained professionals act as restraints hindering its market growth. Scope- Neuromodulation Market, by Technology Internal Neuromodulation Spinal Cord Stimulation Deep Brain Stimulation Vagus Nerve Stimulation Sacral Nerve Stimulation Gastric Electrical Stimulation External Neuromodulation Transcutaneous Electrical Nerve Stimulation Transcranial Magnetic Stimulation Respiratory Electrical Stimulation Some of the major players in the global neuromodulation market include Medtronic, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (U.S.), Synapse Biomedical, Inc. (U.S.), Nevro Corporation (U.S.), Neurosigma, Inc. (U.S.), Neuropace, Inc. (U.S.), Neuronetics, Inc. (U.S.), Cyberonics, Inc. (U.S.), and BioControl Medical (Israel).